ABSTRACT: Neuropathic pain is not well understood. Although central dorsal horn remodelling is likely important in maintaining chronic neuropathic pain, afferent activity from injured nerves or ganglia may initiate these changes. It is suggested, in this review that the peripheral nerve trunk is capable of sustaining a "flare" response as observed in injured skin and other tissues. The injury response may be associated with local vasodilatation, plasma extravasation and the generation of painful local afferent activity sustained by locally originating peptidergic fibers (nervi nervorum). These fibers contain substance P, calcitonin gene-related peptide and other peptides that have been linked to nociceptive transmission. Manipulation of the local injury response of the nerve trunk by pharmacologic means may provide one strategy in the treatment of neuropathic pain. RESUME: Peptides de I'epinevre: ont-ils un role dans la douleur neuropathique? La douleur neuropathique n'est pas bien comprise. Bien que le remodelage de la region centrale de la come superieure soit vraisemblablement important dans le maintien de la douleur chronique neuropathique, l'activite afferente provenent du nerf ou du ganglion endommage peut initier ces changements. Dans cette revue, nous suggerons que le tronc nerveux peripherique est capable de soutenir une reponse amplifiee telle qu'observee dans la peau lesee et dans d'autres tissus. La reponse au dommage peut etre associee avec une vasodilatation locale, une extravasation plasmatique et la production d'activite' afferente locale douloureuse soutenue par des fibres peptidergiques originant localement (nervi nervorum). Ces fibres contiennent de la substance P, des peptides relies genetiquement a la calcitonine et d'autres peptides qui ont ete lies a la transmission nociceptive. La manipulation de la reponse a la lesion locale du tronc nerveux par des moyens pharmacologiques peut offrir une strategic de traitement dans la douleur neuropathique.
Chronic neuropathic pain is a common, but taxing disorder, not only to the patient, but also to the caregiver and to the investigator. The plasticity of sensory systems involved in nociceptive pathways is particularly evident in the dorsal horn of the spinal cord, perhaps the structure most responsible for the maintenance of the chronic pain state.
14 Despite the impressive evidence favoring the crucial role of central sensory structures in the generation of chronic pain, dorsal horn synapses do not remodel of their own accord. Afferent activity from neuromas, injured axons and the dorsal root ganglia are the presumed initiators of central adaptations. 9 There may also be "silent nociceptors" in the peripheral nerve trunk itself that become active during injury or inflammation. 10 How afferent activity from neuropathy generates pain and exactly how the afferent activity arises, however, is not fully understood. Clinical observations add further puzzles. For example, why is it that compression of the median nerve at the carpal tunnel, with an identical degree of sensory conduction slowing, may be exquisitely painful in one patient, but painless or "asymptomatic" in another. There would appear to be very little correlation between endoneurial events that influence conduction velocity and conduction block and those that act as local pain generators.
Asbury and Fields" discussed the origin of neuropathic pain and raised the possibility that sensory fibers innervating the nerve trunk connective tissue (nervi nervorum) might contribute to nerve trunk pain. 1214 Examples of nerve trunk pain may be the deep aching discomfort associated with brachial neuritis or spinal nerve root irritation. A second type of pain may arise directly from injured axons, with hyperaesthesia in the distribution of the injured nerve, as in some "small fiber" polyneuropathies.
In skin, cornea and other tissues, neurogenic inflammation plays an important role in the injury response and in the production of hyperalgesia. 1517 Several mediators have been implicated including the tachykinins substance P (SP), and Neurokinin A (NKA), calcitonin gene-related peptide (CGRP), histamine from mast cells, circulating bradykinin, ATP and others. 16 "axon reflex", or "axon response" enlarging the nocifensor territory and increasing local peptide release. 16 -21 SP, in turn, induces release of histamine from mast cells, increasing the neurogenic inflammatory cycle. SP also participates in vasodilation, plasma extravasation and immune modulation. 22 CGRP is a particularly potent vasodilator, 23 and NKA may contribute toward hyperalgesia. 24 SP and CGRP, modulated by endogenous opioids, may act as synergistic neurotransmitters at the central process of primary afferent fibers as they synapse in the dorsal horn of the spinal cord. [25] [26] [27] It is appealing to suggest that a similar cooperative interaction could occur in the parallel peripheral process of the primary afferent fiber.
If the nervi nervorum hypothesis of Asbury and Fields" is correct, pain generation in damaged nerve trunk connective tissue would require participation of nociceptive sensory fibers and involvement of one or more pain mediators. Finally, it would be helpful to identify adrenergic fibers that could account for "sympathetically maintained" neuropathic pain. All of the requirements for "neurogenic inflammation" and the nervi nervorum hypothesis exist in the peripheral nerve trunk. Vasa nervorum, particularly in the epineurium are innervated by peptidergic fibers with terminals containing SP, CGRP, and others. 13 - 28 The peptidergic fibers probably arise from the parent nerve trunk to innervate its own vasa nervorum and there is evidence of "tonic" peptide release, implying a role in local vasoregulation. 28 Mast cells are present in both the epineurium and endoneurium. 29 The epineurial plexus is also innervated by adrenergic fibers and there is evidence that these fibers have tonic activity. 3003 From work in our laboratory, we have postulated the existence of a "peripheral nerve trunk flare" akin to peptide-mediated flares in other tissues, that could be active under conditions of injury. The nerve trunk flare shares many features with that of skin, for example. It is probably important in the nerve trunk hyperemia induced by remote whole nerve trunk stimulation (akin to the skin hyperemia that occurs following antidromic stimulation of its cutaneous nerve supply). 34 It may be modeled by the acute effects of local capsaicin, that depolarizes nerve terminals through a unique receptor complex and results in acute release of SP, CGRP and probably other neuropeptides. 35 The local flare induced by epineurial capsaicin is immediate, intense and persistent. 28 Moreover, the flare may be prevented on interrupted by antagonists of SP or CGRP, prior capsaicin "desensitization", removal of the epineurial plexus, or administration of systemic antihistamines or cromolyn, acting as a mast cell "stabilizer". 28 - 36 The sensitivity of the capsaicin flare to pharmacological inhibition is interesting and might be explained by a serial multistep process involving several mediators. How these mediators interact, however, is unknown. A hypothesized scheme is illustrated in Figure 1 . Capsaicin nerve trunk hyperemia is locally generated, not requiring the partication of central sensory pathways, and is also inhibited by systemic opiate treatment.
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Of course, there are several critical unanswered questions in a hypothesized linkage between this flare response and the local generation of neuropathic pain. We have preliminary evidence that focal nerve trunk injury from local crush is associated with hyperemia, mediated at least in part by CGRP. 37 It remains to be established whether these peptidergic vascular events arising from sensory fibers also correlate with ascending afferent impulses that are significant enough to remodel and dorsal horn. It would also be interesting to determine if there are peptide 
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Of related interest are recent clinical reports of the efficacy of local capsaicin cream in the treatment of some neuropathic disorders associated with hyperesthesia and allodynia. 3840 The mechanism of topical capsaicin action in these disorders is uncertain. Capsaicin causes conduction block of nociceptive afferents, interrupts axonal transport of SP and may deplete local nociceptive terminals of their peptide contents. 35 - 41 Yet another mechanism may underlie the phenomenon of capsaicin desensitization. 35 -42 There is little evidence that capsaicin cream benefits patients by a neurotoxic action on dorsal root ganglia, as occurs in animals following systemic treatment because sensory function is not permanently interrupted in animals or man by topical application. 43 Capsaicin usually takes repeated applications to be effective, arguing against conduction block or "counter-irritation" as a mechanism of action (although it could be in some patients). It is speculative, but interesting to suggest that the mechanism could be local depletion of SP and CGRP such that local hyperalgesia is not generated. In support of this idea is the observation that capsaicin cream blocks later attempts to evoke a skin flare response. This may be further evidence that there is a close relationship between peptide and histamine-related vascular events and pain generation. 43 If topical capsaicin helps neuropathic pain by reducing peptide concentrations, how might this influence pain generation at a proximal site on the nerve trunk? It is possible that the lack of efficacy of capsaicin cream in some patients with neuropathic pain is a result of more proximal disease activity.
Perhaps most intriguing is the suggestion that opiate analgesics may have an antinociceptive action by interacting with local actions of peptides responsible for pain, vasodilation and plasma extravasation. This would be separate from its known central modulatory effects at the level of the spinal dorsal horn. 44 It is conceivable that local opiate manipulation at sites of neuropathic injury, as recently demonstrated in postsurgical joints, might have a role in the treatment of neuropathic pain. 45 The success of systemic opiates in the treatment of neuropathic pain has been debated, with some workers claiming that this form of pain is opiate unresponsive. 46 Thus, whether modulation of neurogenic inflammation in the peripheral nerve trunk would be helpful in neuropathic pain is speculative. At the very least, our embarrassing lack of success in treating neuropathic pain should mandate a new approach to the problem, perhaps, through the local modulation of neuropeptides.
